Amgen Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Amgen Inc. (AMGN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 0.00% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-14.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2024-02-14
- Amgen Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 0.00%.
- Amgen Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 0.00%, a 100.00% decline from fiscal 2021.
- Amgen Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 4.90%.
- Amgen Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2023-12-31 | 0.00% 10-K · filed 2024-02-14 |
| 2022-12-31 | 0.00% 10-K · filed 2024-02-14 |
| 2021-12-31 | 4.90% 10-K · filed 2024-02-14 |
| 2020-12-31 | 0.00% 10-K · filed 2023-02-09 |
| 2019-12-31 | 0.00% 10-K · filed 2022-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |